Free Lesson Preview
This is just the beginning
The full CRC track covers 8 courses from study start-up to close-out — the skills sponsors actually look for.
View enrollment optionsAlready enrolled? Sign in
Free GCP training
Professional tracks
Clinical Research Coordinator
Full course · Safety Reporting and Pharmacovigilance for CRCs
Free Lesson Preview
The full CRC track covers 8 courses from study start-up to close-out — the skills sponsors actually look for.
View enrollment optionsAlready enrolled? Sign in
Trace the path of adverse event reports from site documentation to regulatory signal detection, understanding why every CRC report matters for patient safety worldwide.
On 30 September 2004, Merck & Co. voluntarily withdrew rofecoxib -- marketed as Vioxx -- from the worldwide market. The drug had been prescribed to approximately 80 million people since its approval in 1999. The reason for withdrawal was unambiguous: data from the APPROVe trial (Adenomatous Polyp Prevention on Vioxx) demonstrated a statistically significant increase in cardiovascular events -- heart attacks and strokes -- in participants taking rofecoxib compared to placebo.
But here is what matters for your work as a clinical research coordinator: that signal did not emerge from a single dramatic moment. It was built, report by report, from individual adverse event documentation at clinical trial sites around the world. Each coordinator who documented a participant's chest pain. Each investigator who assessed a cardiac event. Each site that submitted timely, accurate safety data to the sponsor. The aggregate picture -- the one that eventually prompted a company to pull a billion-dollar product from the market -- was assembled from those individual contributions.
This is the reality of pharmacovigilance. And it begins with you.
Progress saves itself — finish reading and this lesson completes